← FDA DRUG APPROVALS

FDA NDA · NDA021486

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

Sponsor: EMPI

APPLICATION
NDA021486
TYPE
NDA
ORIGINAL APPROVAL
2004-10-26
LATEST ACTION
2004-10-26
ROUTE
IONTOPHORESIS, TOPICAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINEDiscontinued
EPINEPHRINE 0.01MG/ML, LIDOCAINE HYDROCHLORIDE 2% · SOLUTION · IONTOPHORESIS, TOPICAL

Approval history

2004-10-26Type 4 - New Combination · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →